Literature DB >> 15489899

Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells.

Jenny Ekberg1, Göran Landberg, Caroline Holm, Johan Richter, Debra J Wolgemuth, Jenny Liao Persson.   

Abstract

An important role of the cell cycle regulatory protein cyclin A1 in the development of acute myeloid leukemia (AML) was previously demonstrated in a transgenic mouse model. We have now turned our attention to study specific aspects of the activity and subcellular distribution of cyclin A1 using bone marrow samples from normal donors and patients with AML, as well as leukemic cell lines. We show that the localization of cyclin A1 in normal hematopoietic cells is nuclear, whereas in leukemic cells from AML patients and cell lines, it is predominantly cytoplasmic. In leukemic cell lines treated with all-trans retinoic acid (ATRA), cyclin A1 localized to the nucleus. Further, there was a direct interaction between cyclin A1 and cyclin-dependent kinase 1, as well as a major ATRA receptor, RARalpha, in ATRA-treated cells but not in untreated leukemic cells. Our results indicate that the altered intracellular distribution of cyclin A1 in leukemic cells correlates with the status of the leukemic phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15489899     DOI: 10.1038/sj.onc.1208090

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  Function of the A-type cyclins during gametogenesis and early embryogenesis.

Authors:  Debra J Wolgemuth
Journal:  Results Probl Cell Differ       Date:  2011

2.  Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.

Authors:  E Manara; G Basso; M Zampini; B Buldini; C Tregnago; R Rondelli; R Masetti; V Bisio; M Frison; K Polato; G Cazzaniga; G Menna; F Fagioli; P Merli; A Biondi; A Pession; F Locatelli; M Pigazzi
Journal:  Leukemia       Date:  2016-06-28       Impact factor: 11.528

3.  Cyclin A1 regulates the interactions between mouse haematopoietic stem and progenitor cells and their niches.

Authors:  Regina Miftakhova; Andreas Hedblom; Leah Batkiewicz; Lola Anagnosaki; Yuan Zhang; Anita Sjölander; Anette Gjörloff Wingren; Debra J Wolgemuth; Jenny L Persson
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  Post-translational modification of cyclin A1 is associated with staurosporine and TNFalpha induced apoptosis in leukemic cells.

Authors:  Jenny Ekberg; Jenny Liao Persson
Journal:  Mol Cell Biochem       Date:  2008-09-12       Impact factor: 3.396

5.  Cell cycle control in acute myeloid leukemia.

Authors:  Dominik Schnerch; Jasmin Yalcintepe; Andrea Schmidts; Heiko Becker; Marie Follo; Monika Engelhardt; Ralph Wäsch
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

6.  The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia.

Authors:  Maria Francisca Arteaga; Jan-Henrik Mikesch; Jihui Qiu; Jesper Christensen; Kristian Helin; Scott C Kogan; Shuo Dong; Chi Wai Eric So
Journal:  Cancer Cell       Date:  2013-03-18       Impact factor: 31.743

7.  CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.

Authors:  Andreas Hedblom; Kristian B Laursen; Regina Miftakhova; Martuza Sarwar; Lola Anagnostaki; Anders Bredberg; Nigel P Mongan; Lorraine J Gudas; Jenny L Persson
Journal:  Cell Cycle       Date:  2013-03-21       Impact factor: 4.534

8.  Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.

Authors:  Azharuddin Sajid Syed Khaja; Nishtman Dizeyi; Pradeep Kumar Kopparapu; Lola Anagnostaki; Pirkko Härkönen; Jenny Liao Persson
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

9.  Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.

Authors:  Barbara Wegiel; Anders Bjartell; Johanna Tuomela; Nishtman Dizeyi; Martina Tinzl; Leszek Helczynski; Elise Nilsson; Leo E Otterbein; Pirkko Härkönen; Jenny Liao Persson
Journal:  J Natl Cancer Inst       Date:  2008-07-08       Impact factor: 13.506

10.  Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.

Authors:  Martuza Sarwar; Julius Semenas; Regina Miftakhova; Athanasios Simoulis; Brian Robinson; Anette Gjörloff Wingren; Nigel P Mongan; David M Heery; Heather Johnsson; Per-Anders Abrahamsson; Nishtman Dizeyi; Jun Luo; Jenny L Persson
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.